BioMarin, the US-listed rare disease drug developer, is at the centre of vague speculation.
This is paywall protected Betaville Intelligence content. You need to purchase a subscription to access this content. Or get in touch with subscription sales at [email protected] to find out about the different subscription packages on offer.
